Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Libtayo Gains Approval for First-Line NSCLC With Chemotherapy

Nov 09 2022

• By Jessica Merrill

lung cancer — Regeneron's Libtayo added a new lung cancer indication • Source: Shutterstock

Related Content

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

Sep 29 2018

Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data

Aug 04 2022

Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses

Jun 02 2022

Related Companies

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Sanofi

Additional Topics

Approvals ImmunoOncology Research & Development Business Strategies Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window